---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000041"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-05-14T20:06:45+00:00"
generated_at: "2026-05-14T21:00:01.210748+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%

## Summary
- FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.
- Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by >90%.
- Appointed John Bencich as CFO, bringing 25+ years of corporate and capital markets experience.
- Cash and cash equivalents $6.2M at March 31, plus $0.9M April ATM; funds operations into Q3 2026.
- Plans BPD Type 2b meeting in H2 2026 to discuss remaining biosimilar development program.

## SEC filing metadata
- accession: 0001837607-26-000041
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-05-14T20:06:45+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/0001837607-26-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/aeon-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000041
- JSON: https://secwatch.observer/filing/0001837607-26-000041.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000041.txt

## Key facts
- Earnings Releases
  AEON Biopharma, Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 14, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000041/0001837607-26-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.